SPRY4 and ovarian carcinoma: SPRY4 is activated by a target downstream of Wnt7A/Fzd9 signaling [17], PPARγ, which has vital roles in ovarian cancer [18], colorectal cancer [19], and prostate cancer [20], and affects cell growth, differentiation, and metastasis [16].